We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers Squibb Company (BMY - Free Report) is a New York-based major producer and distributor of pharmaceuticals and other healthcare related products. The company’s key oncology products include Opdivo, Sprycel, Yervoy and the recently launched Empliciti. Other than oncology, the company is focused on immunology and cardiovascular drugs like Orencia and Eliquis. It also markets drugs for HBV and HCV like Baraclude and Daklinza. The company’s virology portfolio comprises products like Reyataz and the Sustiva franchise.
Bristol-Myers is also active on partnership front and pursue strategic acquisitions across therapeutic areas including immunoscience, oncology, fibrosis and genetically defined diseases.
However, like many of its peers, Bristol-Myers is facing generic competition for several of its key products. Moreover, its HIV and HCV businesses are under competitive pressure. In this scenario, investor focus remains on company’s high-profile immuno-oncology drug, Opdivo apart from the usual top-and bottom-line numbers.
Bristol-Myers has a mixed record of earnings surprises in the recent quarters. The company’s earnings surpassed expectations in three of the last four quarters, with an average positive surprise of 7.99%
Currently, Bristol-Myers has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings:Bristol-Myers missed on third-quarter 2017 earnings. The company reported EPS of 75 cents while our consensus called for EPS of 77 cents.
Revenues:However, revenues were above expectations. Bristol-Myers posted revenues of $5.3 billion, compared to our consensus estimate of $5.2 billion.
2017 Guidance:Bristol-Myers updated its earnings outlook for 2017. The company expects earnings in the range of $2.95 to $3.05 per share. The Zacks Consensus Estimate for earnings stands at $2.99 per share.
Pre-Market Trading:Shares are up 0.78% in pre-market trading.
Check back later for our full write up on this BMY earnings report later!
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Bristol-Myers (BMY) Q3 Earnings Miss Estimates
Bristol-Myers Squibb Company (BMY - Free Report) is a New York-based major producer and distributor of pharmaceuticals and other healthcare related products. The company’s key oncology products include Opdivo, Sprycel, Yervoy and the recently launched Empliciti. Other than oncology, the company is focused on immunology and cardiovascular drugs like Orencia and Eliquis. It also markets drugs for HBV and HCV like Baraclude and Daklinza. The company’s virology portfolio comprises products like Reyataz and the Sustiva franchise.
Bristol-Myers is also active on partnership front and pursue strategic acquisitions across therapeutic areas including immunoscience, oncology, fibrosis and genetically defined diseases.
However, like many of its peers, Bristol-Myers is facing generic competition for several of its key products. Moreover, its HIV and HCV businesses are under competitive pressure. In this scenario, investor focus remains on company’s high-profile immuno-oncology drug, Opdivo apart from the usual top-and bottom-line numbers.
Bristol-Myers has a mixed record of earnings surprises in the recent quarters. The company’s earnings surpassed expectations in three of the last four quarters, with an average positive surprise of 7.99%
Currently, Bristol-Myers has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings:Bristol-Myers missed on third-quarter 2017 earnings. The company reported EPS of 75 cents while our consensus called for EPS of 77 cents.
Revenues:However, revenues were above expectations. Bristol-Myers posted revenues of $5.3 billion, compared to our consensus estimate of $5.2 billion.
2017 Guidance:Bristol-Myers updated its earnings outlook for 2017. The company expects earnings in the range of $2.95 to $3.05 per share. The Zacks Consensus Estimate for earnings stands at $2.99 per share.
Pre-Market Trading:Shares are up 0.78% in pre-market trading.
Check back later for our full write up on this BMY earnings report later!
Bristol-Myers Squibb Company Price
Bristol-Myers Squibb Company Price | Bristol-Myers Squibb Company Quote
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>